Tessier-Lavigne Marc 的 Form 4/A 修正申報
修正Denali Therapeutics Inc.（DNLI），2022/6/28 申報
- 申報編號
- 0001714899-22-000101
- 申報時間
- 2022/6/28
- 交易日
- 2022/3/23
- 申報延遲
- 97 天
- 10b5-1 計畫
- 表單沒有這欄（2023 年以前）
- 原始申報日
- 2022/3/25
這份申報列了 2 筆非衍生性交易。公開市場賣出合計 $67.7 萬。交易後 97 天申報。
這份修正申報取代了 0001714899-22-000061（2022/3/25 申報）。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Tessier-Lavigne MarcCIK 0001437435 | 董事 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
For this amended Form 4 filing the only change is to add the signature.
- F2
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $32.76 to $33.75 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
表 I 有 1 筆交易的價格引用這則附註。
- F3
Includes 2,074 restricted stock units.
- F4
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $33.76 to $34.69 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
表 I 有 1 筆交易的價格引用這則附註。
- F5
The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 1, for which the Reporting Person serves as trustee.
- F6
The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 2, for which the Reporting Person serves as trustee.
- F7
The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 3, for which the Reporting Person serves as trustee.